BioSpace News Archive

SystemicTx is pleased to announce the appointment of its executive team, characterized by deep experience and proven track records of building and scaling businesses and drug developments across a variety of industries.

Cutera, Inc., a leading provider of laser and energy-based aesthetic systems for practitioners worldwide, announced that it will report financial results for the fourth quarter and full year 2021 after the market close on Tuesday, February 22, 2022.

Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”) a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that it has filed a Pre-Submission package for the Symphony IL-6 Test with the U.S. Food and Drug Administration (“FDA” or “the agency”).

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, announced the appointment of Grant Pickering to its Board of Directors.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), today announced positive topline clinical data from the placebo-controlled, double-blind portion of its Phase 3 MAESTRO-NAFLD-1 (non-alcoholic fatty liver disease) safety study of resmetirom.

Pfizer Inc. (NYSE: PFE) and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the discontinuation of the Pfizer-led clinical development program for vupanorsen (PF-07285557), an investigational antisense therapy that was being evaluated for potential indications in cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG).

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has enrolled the first patient in a Phase IIb study of its drug candidate Namodenoson in the treatment of NASH.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), today reported positive clinical efficacy and safety data for the high dose cohort of 3.5x1014 total vg, as well as long-term durability data across all therapeutic doses of TSHA-120 in giant axonal neuropathy (GAN).

Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced results from the first series of compassionate use cases of Humacyte’s investigational Human Acellular Vessel (HAV) for the treatment of critical limb ischemia and vascular trauma.

Amedisys, Inc., a leading provider of home health, hospice, personal care and higher acuity care services, will report results for the fourth quarter and year ended December 31, 2021, after the market closes on February 23, 2022.